Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project

European Neuropsychopharmacology

Volumn 22, Issue 8, 2012, Pages 569-577

  Franchi, Carlotta ^a   Tettamanti, Mauro ^a   Marengoni, Alessandra ^b   Bonometti, Francesca ^b   Pasina, Luca ^a   Cortesi, Laura ^a   Fortino, Ida ^c   Bortolotti, Angela ^c   Merlino, Luca ^c   Lucca, Ugo ^a   Riva, Emma ^a   Nobili, Alessandro ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Regional Health Ministry   (Italy)

Author keywords

Antipsychotic drugs; Cholinesterase inhibitors; Elderly; Treatment trends

Indexed keywords

CHOLINESTERASE INHIBITOR; CLOTIAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGED; ARTICLE; DRUG SAFETY; DRUG UTILIZATION; ELDERLY CARE; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; COHORT STUDIES; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG LABELING; DRUG PRESCRIPTIONS; FEMALE; GOVERNMENT AGENCIES; HUMANS; ITALY; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 84864570991     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.12.009     Document Type: Article

References (32)

1. Agenzia Italiana del Farmaco (AIFA) website Accessed July 8, 2011. http://www.agenziafarmaco.gov.it/it/content/il-trattamento-farmacologico-dei-disturbi-psicotici-pazienti-affetti-da-demenza.
2. Agenzia Italiana del Farmaco (AIFA) website Accessed July 8, 2011. http://www.agenziafarmaco.gov.it/it/content/trattamento-farmacologico-dei-disturbi-psicotici-nei-pazienti-affetti-da-demenza-aggiornamen.
3. Assogenerici web site Accessed November 11, 2011. http://www.assogenerici.org/2011/centrostudi5.asp?s=2&p=5&modulo=scadenze.
4. Ballard C., Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst. Rev. 2006, (1):CD003476.
5. BMJ group How safe are antipsychotics in dementia?. Drug Ther. Bull. 2007, 45:81-85.
6. Chiabrando G., Bianchi S., Poluzzi E., Montanaro N., Scanavacca P. Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara. Eur. J. Clin. Pharmacol. 2010, 66:661-669.
7. Dorsey E.R., Rabbani A., Gallagher S.A., Conti R.M., Alexander G.C. Impact of FDA black box advisory on antipsychotic medication use. Arch. Intern. Med. 2010, 170(1):96-103.
8. FDA Center for Drug Evaluation and Research FDA information for healthcare professionals on antipsychotics [online] Available from URL:. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm.
9. Fick D.M., Cooper J.W., Wade W.E., Waller J.L., Maclean J.R., Beers M.H. Updating the Beers criteria for potentially inappropriate medication use in older adults. Arch. Intern. Med. 2003, 163:2716-2724.
10. Finkel S.I. Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. J. Clin. Psychiatry 2001, 62:3-6.
11. Hilmer S.N., Gnjidic D. The effects of polypharmacy in older adults. Clin. Pharmacol. Ther. 2009, 85:86-98.
12. Kales H.C., Zivin K., Kim H.M., Valenstein M., Chiang C., Ignacio R.V., Ganoczy D., Cunningham F., Schneider L.S., Blow F.C. Trends in antipsychotic use in dementia 1999-2007. Arch. Gen. Psychiatry 2011, 68(2):190-197.
13. Lee P.E., Gill S.S., Freedman M., Bronskill S.E., Hillmer M.P., Rochon P.A. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004, 329:75. 10.1136/bmj.38125.465579.55.
14. Lopez O.L., Becker J.T., Sweet R.A., Klunk W., Kaufer D.I., Saxton J., DeKosky S.T. Patterns of change in the treatment of psychiatric symptoms in patients with probable Alzheimer's disease from 1983 to 2000. J. Neuropsychiatry Clin. Neurosci. 2003, 15(1):67-73.
15. Lyketsos C.G., Steinberg M., Tschanz J.T., Norton M.C., Steffens D.C., Breitner J.C. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry 2000, 157:708-714.
16. Lyketsos C.G., Lopez O., Jones B., Fitzpatrick A.L., Breitner J., DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA 2002, 288:1475-1483.
17. Ministero della Salute Chiarimenti riguardanti la prescrivibilità dei farmaci antipsicotici atipici da parte delle UVA. Farmacovigilanza News 2004, 7-8:4.
18. National Health Ministry Protocollo di monitoraggio dei piani di trattamento farmacologico per la Malattia di Alzheimer. D.M. del 20/07/2000, S.O. alla G.U. n° 204 del 01/09/2000, e D.M. del 14/03/2001, G.U. n° 86 del 12/04/2001Supplemento ordinario alla G. U. n° 204 del 1° settembre 2000 - Serie Generale 2000.
19. Nobili A., Franchi C., Pasina L., Tettamanti M., Baviera M., Monesi L., Roncaglioni C., Riva E., Lucca U., Bortolotti A., Fortino I., Merlino L. Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-Elderly Project. Pharmacoepidemiol. Drug Saf. 2011, 20:488-496.
20. Parabiaghi A., Franchi C., Tettamanti M., Barbato A., D'Avanzo B., Fortino I., Bortolotti A., Merlino L., Nobili A. Antidepressants utilization among elderly in Lombardy from 2000 to 2007: dispensing trends and appropriateness. Eur. J. Clin. Pharmacol. 2011, 67(10):1077-1083.
21. Percudani M., Barbui C., Fortino I., Petrovich L. Antidepressant drug use in Lombardy, Italy: a population-based study. J. Affect. Disord. 2004, 83:169-175.
22. Pillole.org website Accessed July 8, 2011. http://www.pillole.org/public/aspnuke/news.asp?id=2162&sid=412903068.
23. Rochon P.A., Normand S.L., Gomes T., Gill S.S., Anderson G.M., Melo M., Sykora K., Lipscombe L., Bell C.M., Gurwitz J.H. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch. Intern. Med. 2008, 168(10):1090-1096.
24. Schneeweiss S., Setoguchi S., Brookhart A., Dormuth C., Wang P.S. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007, 176:627-632.
25. Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA 2005, 294:1934-1943.
26. Schneider L.S., Tariot P.N., Dagerman K.S., Davis S.M., Hsiao J.K., Ismail M.S., Lebowitz B.D., Lyketsos C.G., Ryan J.M., Stroup T.S., Sultzer D.L., Weintraub D., Lieberman J.A. Effectiveness of atypical antipsychotics drugs in patients with Alzheimer's disease. N. Engl. J. Med. 2006, 355(15):1525-1538. CATIE-AD Study Group.
27. Sink K.M., Covinsky K.E., Newcomer R., Yaffe K. Ethnic differences in the prevalence and pattern of dementia-related behaviors. J. Am. Geriatr. Soc. 2004, 52:1277-1283.
28. US Department of Health and Human Services Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. Food and Drug Administration Web site Accessed July 1, 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm.
29. Valiyeva E., Herrmann N., Rochon P.A., Gill S.S., Anderson G.M. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 2008, 179(5):438-446.
30. Wang P.S., Schneeweiss S., Avorn J., Fischer M.A., Mogun H., Solomon D.H., Brookhart M.A. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med. 2005, 353(22):2335-2341.
31. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002, 167:1269-1270.
32. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004, 170:1395.